title: [Assessment of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome].
abstract: Sixty patients were randomized to treatment with cytoflavin (n=30) or nootropil (n=30). Patients of the main group received cytoflavin along with standard treatment for correction of hemodynamics. The treatment scheme was as follows: intravenous injections during 10 days, tablets - from 11 to 35 days. The same scheme of treatment was used in the comparison group. The total duration was 35 days. Patients were assessed with NIHSS, the Rankin scale, the Barthel index, MMSE. MRI was used to verify ischemic lesions. The therapeutic efficacy of cytoflavin was significantly higher compared to nootropil in respect to the restoration of neurological functions and self-service abilities as well as to the reduction of cognitive deficit.
authors.forename: M M
authors.initials: MM
authors.lastname: Asadullaev
authors.forename: F S
authors.initials: FS
authors.lastname: Saidvaliev
authors.forename: F K
authors.initials: FK
authors.lastname: Shermukhamedova
authors.forename: Zh K
authors.initials: ZhK
authors.lastname: Rizvonov
authors.forename: N M
authors.initials: NM
authors.lastname: Vakhabova
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D013386:Succinates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D010889:Piracetam